Regeneron Pharmaceuticals (REGN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

REGN Regeneron Pharmaceuticals

Watchlist

1138.810
-7.940-0.69%

Close Sep 18 16:00 ET

1146.750
+7.940+0.70%

Post 16:27 ET

125.54BMarket Cap30.15P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,282
Moomoo NewsSep 17 07:34 ET · Ratings
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,300
Moomoo NewsSep 17 07:34 ET · Ratings
BofA Securities Initiates Regeneron Pharmaceuticals(REGN.US) With Sell Rating, Announces Target Price $805
Moomoo NewsSep 17 05:33 ET · Ratings
Express News | Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $1015 Price Target
BenzingaSep 16 12:59 ET
Regeneron Pharmaceuticals Analyst Ratings
BenzingaSep 16 12:57 ET · Ratings
Cramer's Week Ahead: Fed Rate Decision, Earnings From Darden and Cracker Barrel
CNBCSep 13 18:40 ET

Comments

Meltyy

Sep 10 04:37

📅 FDA PDUFA & AdCom Update…

📣 ITRM AdCom 9/9 meeting ongoing 🚗
👀 stay tuned for updates on meeting outcomes
See 👇 for further info.
🚨 This Week’s AdCom:
$Iterum Therapeutics (ITRM.US)$ : Meeting ongoing 🤔
⇨ Sulopenem
‣ uUTI (Uncomplicated Urinary Tract Infection)
‣ AdCom: 9/9/24
🚨 Last Week’s PDUFAs:
$Travere Therapeutic (TVTX.US)$ : Approved 9/5 🎉
⇨ FILSPARI (Sparsentan)
‣ IgA nephropathy (IgAN)
‣ PDUFA: 9/5/24
$Avadel Pharmaceuticals (AVDL.US)$ : Awaiting decision 🤔
⇨ LUMRYZ (sodium oxybate)
‣...

Analysts Notebook

Aug 27 06:33

Columns Ready for Fed Rate Cuts? Biotech's Potential to Watch

The Federal Reserve appears poised to cut interest rates later this year. While the broader stock market might breathe a sigh of relief, certain sectors could be more significantly impacted than others. Biotechnology could be one of those sectors - at least, that's what Morgan Stanley believes.
In 2024, biotech stocks had a slow start, with the S&P Biotechnology Select Industry Index returning just under 4% in the first six months, compared to...

A half-point cut! The Fed chooses an aggressive start to its easing campaign

Meltyy

Aug 27 01:16

FDA PDUFA Update:

🚀 Buckle up for upcoming PDUFAs in September! 👇
$Travere Therapeutic (TVTX.US)$ : FILSPARI (Sparsentan)
$Avadel Pharmaceuticals (AVDL.US)$ : LUMRYZ (FT218)
$Iterum Therapeutics (ITRM.US)$ : Sulopenem - AdCom 🗓️
$Sanofi (SNY.US)$ & $Regeneron Pharmaceuticals (REGN.US)$ : Dupixent
$Vanda Pharmaceuticals (VNDA.US)$ : Tradipitant
$Zevra Therapeutics (ZVRA.US)$ : Arimoclomol
$Heron Therapeutics (HRTX.US)$ : ZYNRELEF® Vial Access Needle
$Merck & Co (MRK.US)$ : KEYTRUDA+ chemotherapy
$Bristol-Myers Squibb (BMY.US)$ : KarXT (...

frankinglily

Aug 25 22:03

Argument:
The upcoming interest rate cuts are poised to benefit the biotech stock industry, setting the stage for strong performance in the coming quarters.
Reasons:
Cheaper Funding: Lower interest rates make it easier for biotech companies to access capital for research and development, accelerating their progress and growth potential.
Attractive Valuations: Biotech stocks are currently trading at attractive levels, offering investors an opportunity to capitalize on the sector's long-term pot...